GPC3 and neoplasm: For instance, GPC3-targeted chimeric antigen receptor (CAR) T cell therapy has shown promising safety and preliminary efficacy in early-phase clinical trials (e.g., NCT03130712, NCT05352542), demonstrating tumor infiltration and disease stabilization.